Outpatient Parenteral Antimicrobial Therapy in Children
Purpose of Review
Over recent years, there has been a marked increase in the number of centres delivering paediatric outpatient parenteral antimicrobial therapy (pOPAT). Various factors have fuelled this drive, including the significant economic pressures faced by high-income countries to contain the cost of healthcare, resulting in a significant reduction of in-patient beds over the past 20 years. It is essential that pOPAT services have formal clinical governance structures in place to ensure the safe and effective management of children being ambulated on intravenous antibiotics. They also require oversight of antimicrobial decisions by a medically qualified infection specialist to ensure that the principles of antimicrobial stewardship are adhered to. This review aims to provide an evidence-based framework for delivering pOPAT services.
There is increasing data supporting the implementation of admission avoidance strategies for children with cellulitis and pyelonephritis. In addition, recent data supports the management of a subset of children with febrile neutropenia within pOPAT services. Above all, there is a clear recognition that embedding antimicrobial stewardship within pOPAT services reduces duration of intravenous antibiotics (IVAbs) and improves patient management.
pOPAT services are safe, cost-effective and associated with high levels of parent/patient satisfaction. Further research is required to develop risk prediction models for children being considered for pOPAT. Further data about the use of elastomeric devices in children and the acceptability of parental administration of IVAbs are also required.
KeywordsOutpatient parenteral antimicrobial therapy Antimicrobial stewardship Antibiotic stewardship pOPAT Hospital at home Ambulatory antibiotics Children Paediatrics
Compliance with Ethical Standards
Conflict of Interest
Sanjay Patel and Helen Green declare that they have no conflict of interest.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 1.•• Patel S, Abrahamson E, Goldring S, Green H, Wickens H, Laundy M. Good practice recommendations for paediatric outpatient parenteral antibiotic therapy (p-OPAT) in the UK: a consensus statement. J Antimicrob Chemother. 2015;70(2):360–73 An evidence based national guideline covering all the areas involved in setting up and running a pOPAT service. CrossRefPubMedGoogle Scholar
- 5.Minton J, Murray CC, Meads D, Hess S, Vargas-Palacios A, Mitchell E, et al. The community IntraVenous antibiotic study (CIVAS): a mixed-methods evaluation of patient preferences for and cost-effectiveness of different service models for delivering outpatient parenteral antimicrobial therapy. Southampton: Health Services and Delivery Research; 2017.Google Scholar
- 8.Peltola H, Paakkonen M, Kallio P, Kallio MJ. Osteomyelitis-septic arthritis study G. Prospective, randomized trial of 10 days versus 30 days of antimicrobial treatment, including a short-term course of parenteral therapy, for childhood septic arthritis. Clin Infect Dis. 2009;48(9):1201–10.CrossRefPubMedGoogle Scholar
- 14.• Hersh AL, Olson J, Stockmann C, Thorell EA, Knackstedt ED, Esquibel L, et al. Impact of antimicrobial stewardship for pediatric outpatient parenteral antibiotic therapy. J Pediatric Infect Dis Soc. 2018;7(2):e34–e6 Clear demonstration of the importunate of embedding antimicrobial stewardship principles within an pOPAT service; this study describes the impact of expert review on antibiotic use. CrossRefPubMedGoogle Scholar
- 16.Xu M, Doan Q. Outpatient Parenteral Antimicrobial Therapy and Judicious Use of Pediatric Emergency Resources. Pediatr Emerg Care. 2017.Google Scholar
- 21.•• McMullan BJ, Andresen D, Blyth CC, Avent ML, Bowen AC, Britton PN, et al. Antibiotic duration and timing of the switch from intravenous to oral route for bacterial infections in children: systematic review and guidelines. Lancet Infect Dis. 2016;16(8):e139–52 Evidence based guidelines on the treatment of infections in children. CrossRefPubMedGoogle Scholar
- 24.Durojaiye OC, Kritsotakis EI, Johnston P, Kenny T, Ntziora F, Cartwright K. Developing a risk prediction model for 30-day unplanned hospitalization in patients receiving outpatient parenteral antimicrobial therapy. Clin Microbiol Infect. 2018.Google Scholar
- 27.Scanlan BT, Ibrahim LF, Hopper SM, Babl FE, Davidson A, Bryant PA. Selected children with complicated acute urinary tract infection may be treated with outpatient parenteral antibiotic therapy at home directly from the emergency department. Pediatr Infect Dis J. 2019;38(2):e20–e5.CrossRefPubMedGoogle Scholar
- 30.•• Bryant PA, Katz NT. Inpatient versus outpatient parenteral antibiotic therapy at home for acute infections in children: a systematic review. Lancet Infect Dis. 2018;18(2):e45–54 An excellent systematic review of the evidence for managing children within pOPAT services. CrossRefPubMedGoogle Scholar
- 34.• Jenkins A, Hills T, Santillo M, Gilchrist M. Drug Stability Working Group of the BUKOI. Extended stability of antimicrobial agents in administration devices. J Antimicrob Chemother. 2017;72(4):1217–20 A review of the literature on the stability of antimicrobials within elastomeric devices. Demonstrates a paucity of high-quality stability data. PubMedGoogle Scholar
- 35.• Allwood MC, Stonkute D, Wallace A, Wilkinson A-S, Hills T, Jamieson C. Assessment of the stability of citrate-buffered flucloxacillin for injection when stored in two commercially available ambulatory elastomeric devices: INfusor LV (Baxter) and Accufuser (Woo Young Medical): a study compliant with the NHS Yellow Cover Document (YCD) requirements. 2018:ejhpharm-2018-001515. Data on flucloxacillin stability over 24-hours within 2 different elastomeric devices. Demonstrates the importance of citrate-buffering to ensure drug stability over a 24 hour period. Google Scholar
- 36.Jamieson C, Allwood MC, Stonkute D, Wallace A, Wilkinson A-S, Hills T. Investigation of meropenem stability after reconstitution: the influence of buffering and challenges to meet the NHS Yellow Cover Document compliance for continuous infusions in an outpatient setting. 2019:ejhpharm-2018-001699.Google Scholar